Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.78 |
| ▸ | PTGDR | Q13258 | 8/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189148 | 0.88 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL2214672 | 0.84 | PTGDR2 (1.00) | PTGDR2PTGDR | |
| SCHEMBL15518279 | 0.84 | PTGDR2 (1.00) | PTGDR2PTGDR | |
| SCHEMBL2215872 | 0.84 | PTGDR2 (1.00) | PTGDR2PTGDR | |
| SCHEMBL2190659 | 0.81 | PTGDR2 (0.88) | PTGDR2PTGDR | |
| SCHEMBL2188049 | 0.80 | PTGDR2 (0.86) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL3088522 | 0.78 | PTGDR2 (0.64) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL2214398 | 0.77 | PTGDR2 (0.86) | PTGDR2PTGDR | |
| SCHEMBL2188102 | 0.77 | PTGDR2 (0.80) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL15519218 | 0.77 | PTGDR2 (0.87) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346865-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2015-07-15 | — | — | EP | disclosed |
| US-8637671-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-8637671-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-14 | — | — | US | disclosed |
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-14 | — | — | US | disclosed |
| WO-2010031183-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | PTGDR2 2/4885PTGDR 3/4885TBXA2R 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.